Back to top
more

Trevi Therapeutics (TRVI)

(Delayed Data from NSDQ)

$2.54 USD

2.54
179,222

-0.11 (-4.15%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $2.55 +0.01 (0.39%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick

by Zacks Equity Research

Trevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Trevi Therapeutics, Inc. (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Trevi Therapeutics, Inc. (TRVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Trevi Therapeutics, Inc. (TRVI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

Trevi Therapeutics, Inc. (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Trevi Therapeutics, Inc. (TRVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Trevi Therapeutics, Inc. (TRVI) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Trevi Therapeutics, Inc. (TRVI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is a Surprise Coming for Trevi Therapeutics (TRVI) This Earnings Season?

by Zacks Equity Research

Trevi Therapeutics (TRVI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is AVEO Pharmaceuticals (AVEO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AVEO Pharmaceuticals (AVEO) and Trevi Therapeutics, Inc. (TRVI) have performed compared to their sector so far this year.

Is AVEO Pharmaceuticals (AVEO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AVEO Pharmaceuticals (AVEO) and Trevi Therapeutics, Inc. (TRVI) have performed compared to their sector so far this year.

Merck (MRK) Q1 Earnings & Sales Beat, COVID Drug Adds $3.3B

by Zacks Equity Research

Merck (MRK) beats Q1 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.

Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise

by Zacks Equity Research

Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines. Consumer healthcare sales remain strong.

Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon

by Zacks Equity Research

The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly.

KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study

by Zacks Equity Research

KemPharm (KMPH) initiates dosing in a phase I study to evaluate the cardiovascular safety profile of its lead pipeline candidate, KP1077's sole active API, serdexmethylphenidate.

TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down

by Zacks Equity Research

TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.

Are You Looking for a Top Momentum Pick? Why Trevi Therapeutics, Inc. (TRVI) is a Great Choice

by Zacks Equity Research

Does Trevi Therapeutics, Inc. (TRVI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Moderna (MRNA) Initiates Early-Stage Flu Vaccine Study

by Zacks Equity Research

Moderna's (MRNA) two vaccine candidates, mRNA-1020 and mRNA-1030, target both hemagglutinin and neuraminidase protein for providing better protection against the influenza virus. The company initiates a phase I/II study.

Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study

by Zacks Equity Research

Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.

Rhythm Pharmaceuticals (RYTM) Down Due to Study Design Changes

by Zacks Equity Research

Rhythm Pharmaceuticals (RYTM) modifies the design of its two genetic obesity disorder studies to focus on rare patients, thus reducing the targeted population size. RYTM expects to save costs in the process.

Reata (RETA) Submits NDA for Friedreich's Ataxia Candidate

by Zacks Equity Research

Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. It completes the rolling submission of an NDA for the same. Stock rises.

argenx (ARGX) Up on Positive Autoimmune Disorder Study Data

by Zacks Equity Research

argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.

Here's Why Trevi Therapeutics, Inc. (TRVI) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

Trevi Therapeutics, Inc. (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Sanghamitra Saha headshot

5 Stocks With Rising P/E Are Good Buys

by Sanghamitra Saha

Bet on top-ranked stocks STKL, LZB, ONCY, TPR and TRVI that have rising P/E to realize outsized gains.

Here's Why Trevi Therapeutics, Inc. (TRVI) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Trevi Therapeutics, Inc. (TRVI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Trevi Therapeutics' (TRVI) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Trevi Therapeutics (TRVI).